Camp4 Therapeutics Corp (CAMP) shareholders
CAMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3057% above fair value
$3.80−0.29 (-7.09%)
Close on Nov 13, 2026Market cap $238.46MP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
66.5%
42M of 63M shares
Institutional holders
61
23 new, 7 sold out
Net institutional buying
8M
In Q2 2026
Insider trades, 12 months
5 buys · 6 sales
Net sold $2.40M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Andrew J. Schwab Joint filing with Kush Parmar (9.90%), 5AM Ventures VII, L.P. (6.30%) and 1 more | 6,379,125 | 9.90% | 13D (active) amendment | Aug 27, 2026 |
| Janus Henderson Group PLC | 6,307,636 | 12.20% | 13G (passive) | Dec 31, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (9.50%) | 4,918,243 | 9.50% | 13G (passive) amendment | Dec 31, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (7.80%) | 4,908,857 | 7.80% | 13G (passive) amendment | Sep 30, 2026 |
| Coastlands Capital LP Joint filing with Coastlands Capital Partners LP (9.99%), Coastlands Capital GP LLC (9.99%) and 2 more | 4,886,722 | 9.99% | 13G (passive) amendment | Sep 10, 2025 |
| Amir Nashat | 3,932,251 | 6.30% | 13D (active) amendment | Aug 13, 2026 |
| Vivo Opportunity Fund Holdings, L.P. Joint filing with Vivo Opportunity, LLC (7.40%) | 3,856,991 | 7.40% | 13G (passive) amendment | Dec 31, 2025 |
| Trails Edge Capital Partners, LP Joint filing with Trails Edge Biotechnology Master Fund, LP (6.00%), Ortav Yehudai (6.00%) | 3,790,636 | 6.00% | 13G (passive) | Aug 3, 2026 |
| Everest Aggregator, LP Joint filing with Enavate Sciences GP, LLC (6.00%) | 3,127,360 | 6.00% | 13D (active) amendment | Dec 19, 2025 |
| Bam Gp LLC Joint filing with Balyasny Asset Management L.P. (5.07%), Balyasny Asset Management Holdings LP (5.07%) and 2 more | 2,632,437 | 5.07% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CAMP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 6,307,636 | 10.05% | $27.58M | New | 0.01% |
| 5AM Venture Management, LLC | 5,869,091 | 9.35% | $25.65M | – | 8.91% |
| FMR LLC | 4,904,339 | 7.82% | $21.43M | −29,093 | 0.00% |
| Vivo Capital, LLC | 4,246,568 | 6.77% | $18.56M | – | 1.69% |
| Balyasny Asset Management L.P. | 2,575,724 | 4.10% | $11.26M | −56,713 | 0.01% |
| a16z Capital Management, L.L.C. | 2,125,339 | 3.39% | $9.29M | – | 0.07% |
| Adage Capital Partners Gp, L.L.C. | 1,960,784 | 3.12% | $8.57M | – | 0.01% |
| Trails Edge Capital Partners, LP | 1,932,937 | 3.08% | $8.45M | −6,626 | 1.34% |
| BlackRock, Inc. | 1,644,134 | 2.62% | $7.18M | +1,187,763 | 0.00% |
| Vanguard Capital Management LLC | 1,533,489 | 2.44% | $6.70M | −1,279 | 0.00% |
| Enavate Sciences Gp, LLC | 1,425,541 | 2.27% | $6.23M | −765,379 | 1.80% |
| Stonepine Capital Management, LLC | 1,389,622 | 2.21% | $6.07M | – | 3.43% |
| HarbourVest Partners LLC | 1,271,948 | 2.03% | $5.56M | – | 3.27% |
| Geode Capital Management, LLC | 795,651 | 1.27% | $3.48M | +412,830 | 0.00% |
| SummitTX Capital, L.P. | 725,160 | 1.16% | $3.17M | +385,639 | 0.08% |
| Silverarc Capital Management, LLC | 653,594 | 1.04% | $2.86M | – | 0.30% |
| State Street Corp | 362,300 | 0.58% | $1.58M | +215,400 | 0.00% |
| Northern Trust Corp | 248,673 | 0.40% | $1.09M | +178,007 | 0.00% |
| Goldman Sachs Group Inc | 241,393 | 0.38% | $1.05M | +163,048 | 0.00% |
| Vanguard Fiduciary Trust Co | 226,074 | 0.36% | $987.94K | +31,061 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 61 | 42M | 66.5% | 23 / 15 | 12 / 7 | 10M | 2M |
| Q1 2026 | 46 | 40M | 63.4% | 14 / 15 | 9 / 7 | 5M | 2M |
| Q4 2025 | 40 | 38M | 60.9% | 13 / 11 | 10 / 2 | 12M | 2M |
| Q3 2025 | 29 | 28M | 45.0% | 8 / 4 | 11 / 8 | 17M | 0M |
| Q2 2025 | 29 | 12M | 18.7% | 7 / 6 | 11 / 17 | 0M | 1M |
| Q1 2025 | 39 | 13M | 20.2% | 7 / 11 | 11 / 4 | 0M | 0M |
| Q4 2024 | 36 | 13M | 20.5% | 36 / 0 | 0 / 0 | 13M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
48 funds held CAMP in Q2 2026, 45% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CAMP | Value | % of fund | As of |
|---|---|---|---|---|---|
| Select Biotechnology Portfolio | 1,326,208 | 2.11% | $5.82M | 0.11% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,139,169 | 1.82% | $4.98M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 453,046 | 0.72% | $1.98M | 0.00% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 400,071 | 0.64% | $1.76M | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 357,195 | 0.57% | $1.56M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 341,836 | 0.54% | $1.18M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 267,733 | 0.43% | $1.17M | 0.01% | Jun 30, 2026 |
| Victory Science & Technology Fund | 226,602 | 0.36% | $781.78K | 0.05% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 165,086 | 0.26% | $724.73K | 0.00% | May 31, 2026 |
| Fidelity Growth Company K6 Fund | 109,513 | 0.17% | $480.76K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 103,784 | 0.17% | $453.54K | 0.03% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 76,660 | 0.12% | $264.48K | 0.00% | Jul 31, 2026 |
| Fidelity Series Growth Company Fund | 62,923 | 0.10% | $276.23K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 61,034 | 0.10% | $267.94K | 0.00% | May 31, 2026 |
| Victory RS Science & Technology Fund | 58,930 | 0.09% | $257.52K | 0.10% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Josh Mandel-Brehm | Chief Executive Officer, Director | 284,968 | 0.45% | Aug 5, 2026 |
| Kelly Gold | Chief Financial Officer | 86,467 | 0.14% | Sep 2, 2026 |
| Daniel Tardiff | Chief Scientific Officer | 0 | – | Aug 19, 2026 |
| Yuri Maricich | Chief Medical Officer | 12,611 | 0.02% | Aug 5, 2026 |
| David Bumcrot | Chief Scientific Officer | 61,741 | 0.10% | Apr 3, 2025 |
| Andrew J. Schwab | Director | 5,277,216 | 8.41% | Aug 31, 2026 |
| Richard A. Young | Director | 186,388 | 0.30% | Aug 5, 2026 |
| Murray Stewart | Director | – | – | Jun 12, 2026 |
| Douglas E. Williams | Director | 2,501 | 0.00% | Jun 12, 2026 |
| Steven H. Holtzman | Director | 108,946 | 0.17% | Jun 12, 2026 |
| Amir Nashat | Director, 10% owner | 197,661 | 0.31% | Jun 12, 2026 |
| Michael F. MacLean | Director | – | – | Apr 3, 2026 |
| Michael J. Higgins | Director | 28,739 | 0.05% | Jun 27, 2025 |
| Paula Ragan | Director | 20,232 | 0.03% | Jun 27, 2025 |
| James P. Boylan | Director | – | – | Jun 27, 2025 |
| Ravi I. Thadhani | Director | 17,014 | 0.03% | Jun 27, 2025 |
| 5AM Partners VII, LLC | 10% owner | – | – | Aug 5, 2026 |
| 5AM Opportunities II (GP), LLC | 10% owner | – | – | Aug 5, 2026 |
| 5AM Opportunities II, L.P. | 10% owner | 2,927,915 | 4.67% | Aug 5, 2026 |
| 5AM Partners VI, LLC | 10% owner | – | – | Aug 5, 2026 |
| 5AM Ventures VII, L.P. | 10% owner | 5,869,091 | 9.35% | Aug 5, 2026 |
| Kush Parmar | 10% owner | – | – | Aug 5, 2026 |
| 5AM Ventures VI, L.P. | 10% owner | – | – | Aug 5, 2026 |
| Polaris Partners GP X, L.L.C. | 10% owner | – | – | Sep 11, 2025 |
| Brian Chee | 10% owner | – | – | Sep 11, 2025 |
| Polaris Management Co. VII, L.L.C. | 10% owner | 2,825,500 | 4.50% | Sep 11, 2025 |
| Polaris Partners VII, L.P. | 10% owner | 1,603,779 | 2.56% | Sep 11, 2025 |
| Polaris Entrepreneurs' Fund VII, L.P. | 10% owner | – | – | Sep 11, 2025 |
| Amy W. Schulman | 10% owner | 909,090 | 1.45% | Sep 11, 2025 |
| Polaris Partners X, L.P. | 10% owner | 909,090 | 1.45% | Sep 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kelly Gold Chief Financial Officer | Aug 31, 2026 | Buy | +10,000 | $3.96 | $39.60K | 10,000 |
| Andrew J. Schwab Director | Aug 27, 2026 | Sale | −400,000 | $4.04 | $1.62M | 2,033,270 |
| Andrew J. Schwab Director | Aug 24, 2026 | Sale | −10 | $4.50 | $45 | 2,433,270 |
| Andrew J. Schwab Director | Aug 21, 2026 | Sale | −32,018 | $4.50 | $144.08K | 2,433,280 |
| Andrew J. Schwab Director | Aug 20, 2026 | Sale | −114,700 | $4.54 | $520.74K | 2,465,298 |
| Andrew J. Schwab Director | Aug 19, 2026 | Sale | −45,147 | $4.76 | $214.90K | 2,579,998 |
| Daniel Tardiff Chief Scientific Officer | Aug 19, 2026 | Sale | −1,738 | $4.76 | $8.27K | 0 |
| Yuri Maricich Chief Medical Officer | Aug 3, 2026 | Buy | +6,551 | $1.65 | $10.81K | 12,611 |
| Josh Mandel-Brehm Chief Executive Officer, Director | Aug 3, 2026 | Buy | +6,551 | $1.65 | $10.81K | 284,968 |
| Richard A. Young Director | Aug 3, 2026 | Buy | +16,378 | $1.65 | $27.02K | 186,388 |
| Kelly Gold Chief Financial Officer | Aug 3, 2026 | Buy | +6,551 | $1.65 | $10.81K | 74,428 |
| 5AM Ventures VII, L.P. 10% owner | Sep 11, 2025 | Buy | +2,941,176 | $1.53 | $4.50M | 2,941,176 |
| Andrew J. Schwab Director, 10% owner | Sep 11, 2025 | Award | +2,941,176 | $1.53 | $4.50M | 2,941,176 |
| Polaris Management Co. VII, L.L.C. 10% owner | Sep 11, 2025 | Buy | +1,221,721 | $1.53 | $1.87M | 2,825,500 |
| Polaris Management Co. VII, L.L.C. 10% owner | Sep 11, 2025 | Buy | +85,468 | $1.53 | $130.77K | 197,661 |
| Amir Nashat Director, 10% owner | Sep 11, 2025 | Buy | +85,468 | $1.53 | $130.77K | 197,661 |
| Amir Nashat Director, 10% owner | Sep 11, 2025 | Buy | +1,221,721 | $1.53 | $1.87M | 2,825,500 |
| Kelly Gold Chief Financial Officer | Sep 11, 2025 | Buy | +6,060 | $1.65 | $10.00K | 67,877 |
| Richard A. Young Director | Sep 11, 2025 | Buy | +15,151 | $1.65 | $25.00K | 170,010 |
| Josh Mandel-Brehm Chief Executive Officer, Director | Sep 11, 2025 | Buy | +6,060 | $1.65 | $10.00K | 278,417 |
| Yuri Maricich Chief Medical Officer | Sep 11, 2025 | Buy | +6,060 | $1.65 | $10.00K | 6,060 |
| Polaris Management Co. VII, L.L.C. 10% owner | Oct 15, 2024 | Conversion | +24,745 | – | – | 112,193 |
| Polaris Management Co. VII, L.L.C. 10% owner | Oct 15, 2024 | Conversion | +353,718 | – | – | 1,603,779 |
| Polaris Management Co. VII, L.L.C. 10% owner | Oct 15, 2024 | Conversion | +87,448 | – | – | 87,448 |
| Polaris Management Co. VII, L.L.C. 10% owner | Oct 15, 2024 | Conversion | +1,250,061 | – | – | 1,250,061 |
| Polaris Management Co. VII, L.L.C. 10% owner | Oct 15, 2024 | Buy | +909,090 | $11.00 | $10.00M | 909,090 |
| AH Equity Partners Bio I, L.L.C. 10% owner | Oct 15, 2024 | Conversion | +1,398,067 | – | – | 1,398,067 |
| AH Equity Partners Bio I, L.L.C. 10% owner | Oct 15, 2024 | Buy | +545,454 | $11.00 | $6.00M | 545,454 |
| AH Equity Partners Bio I, L.L.C. 10% owner | Oct 15, 2024 | Buy | +181,818 | $11.00 | $2.00M | 1,579,885 |
| Northpond Ventures II, LP 10% owner | Oct 15, 2024 | Buy | +763,636 | $11.00 | $8.40M | 763,636 |
| Northpond Ventures II, LP 10% owner | Oct 15, 2024 | Conversion | +471,415 | – | – | 471,415 |
| Northpond Ventures II, LP 10% owner | Oct 15, 2024 | Conversion | +1,003,193 | – | – | 1,003,193 |
| Everest Aggregator, LP 10% owner | Oct 15, 2024 | Buy | +1,363,636 | $11.00 | $15.00M | 3,785,802 |
| Everest Aggregator, LP 10% owner | Oct 15, 2024 | Conversion | +2,422,166 | – | – | 2,422,166 |
| Polaris Partners VII, L.P. 10% owner | Oct 15, 2024 | Conversion | +353,718 | – | – | 1,603,779 |
| Polaris Partners VII, L.P. 10% owner | Oct 15, 2024 | Buy | +909,090 | $11.00 | $10.00M | 909,090 |
| Polaris Partners VII, L.P. 10% owner | Oct 15, 2024 | Conversion | +24,745 | – | – | 112,193 |
| Polaris Partners VII, L.P. 10% owner | Oct 15, 2024 | Conversion | +1,250,061 | – | – | 1,250,061 |
| Polaris Partners VII, L.P. 10% owner | Oct 15, 2024 | Conversion | +87,448 | – | – | 87,448 |
| Steven H. Holtzman Director | Oct 15, 2024 | Conversion | +8,917 | – | – | 108,946 |
| Richard A. Young Director | Oct 15, 2024 | Conversion | +8,917 | – | – | 154,859 |
| Josh Mandel-Brehm Chief Executive Officer, Director | Oct 15, 2024 | Conversion | +605 | – | – | 272,357 |
| Andrew J. Schwab Director, 10% owner | Oct 15, 2024 | Conversion | +1,337,592 | – | – | 1,337,592 |
| Andrew J. Schwab Director, 10% owner | Oct 15, 2024 | Buy | +909,090 | $11.00 | $10.00M | 2,625,145 |
| Andrew J. Schwab Director, 10% owner | Oct 15, 2024 | Conversion | +302,770 | – | – | 302,770 |
| Andrew J. Schwab Director, 10% owner | Oct 15, 2024 | Conversion | +378,463 | – | – | 1,716,055 |
| 5AM Opportunities II, L.P. 10% owner | Oct 15, 2024 | Buy | +909,090 | $11.00 | $10.00M | 2,625,145 |
| 5AM Opportunities II, L.P. 10% owner | Oct 15, 2024 | Conversion | +302,770 | – | – | 302,770 |
| 5AM Opportunities II, L.P. 10% owner | Oct 15, 2024 | Conversion | +1,716,055 | – | – | 1,716,055 |
| Amir Nashat Director, 10% owner | Oct 15, 2024 | Conversion | +24,745 | – | – | 112,193 |
| Amir Nashat Director, 10% owner | Oct 15, 2024 | Conversion | +1,250,061 | – | – | 1,250,061 |
| Amir Nashat Director, 10% owner | Oct 15, 2024 | Conversion | +87,448 | – | – | 87,448 |
| Amir Nashat Director, 10% owner | Oct 15, 2024 | Conversion | +353,718 | – | – | 1,603,779 |
| Amir Nashat Director, 10% owner | Oct 15, 2024 | Buy | +909,090 | $11.00 | $10.00M | 909,090 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
6.63%
3M shares short
Days to cover
23.7
At 0M shares a day
Change since last report
-5.6%
From 3M shares
Short volume, 20 days
35.5%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Camp4 Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 428,835 shares on Sep 4, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Daniel Tardiff affiliate | Aug 19, 2026 | 1,738 | $8.28K | Aug 19, 2026 | 434 ESPP Issuance |
See a number that looks wrong?